These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9117554)

  • 1. Neurochemical correlates of dementia.
    Procter AW
    Neurodegeneration; 1996 Dec; 5(4):403-7. PubMed ID: 9117554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical studies of Alzheimer's disease.
    Palmer AM
    Neurodegeneration; 1996 Dec; 5(4):381-91. PubMed ID: 9117551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical pathology and treatment strategies in Alzheimer's disease: emphasis on the cholinergic system.
    Winblad B; Messamore E; O'Neill C; Cowburn R
    Acta Neurol Scand Suppl; 1993; 149():4-6. PubMed ID: 8128837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease.
    Wood PL; Etienne P; Lal S; Nair NP; Finlayson MH; Gauthier S; Palo J; Haltia M; Paetau A; Bird ED
    J Neurol Sci; 1983 Dec; 62(1-3):211-7. PubMed ID: 6142096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease.
    Palmer AM; Procter AW; Stratmann GC; Bowen DM
    Neurosci Lett; 1986 May; 66(2):199-204. PubMed ID: 3014387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcholine receptor targets on cortical pyramidal neurones as targets for Alzheimer's therapy.
    Chessell JP
    Neurodegeneration; 1996 Dec; 5(4):453-9. PubMed ID: 9117562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between neuropathological and neurochemical changes.
    Mountjoy CQ
    Br Med Bull; 1986 Jan; 42(1):81-5. PubMed ID: 3513896
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuropathologic and neurochemical correlates of psychosis in primary dementia.
    Zubenko GS; Moossy J; Martinez AJ; Rao G; Claassen D; Rosen J; Kopp U
    Arch Neurol; 1991 Jun; 48(6):619-24. PubMed ID: 1710105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurotransmitter anomalies in Alzheimer's disease].
    Berger B
    Rev Neurol (Paris); 1984; 140(10):539-52. PubMed ID: 6150545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects.
    Procter AW; Francis PT; Holmes C; Webster MT; Qume M; Stratmann GC; Doshi R; Mann DM; Harrison PJ; Pearson RC
    Acta Neuropathol; 1994; 88(6):545-52. PubMed ID: 7879601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa.
    Davies P; Katzman R; Terry RD
    Nature; 1980 Nov; 288(5788):279-80. PubMed ID: 6107862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotransmitters and second messengers in aging and Alzheimer's disease.
    Francis PT; Webster MT; Chessell IP; Holmes C; Stratmann GC; Procter AW; Cross AJ; Green AR; Bowen DM
    Ann N Y Acad Sci; 1993 Sep; 695():19-26. PubMed ID: 7902054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of neurofibrillary tangles in parvalbumin-immunoreactive interneurones in the cerebral cortex of Alzheimer-type dementia brain.
    Iwamoto N; Emson PC
    Neurosci Lett; 1991 Jul; 128(1):81-4. PubMed ID: 1717900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotrophic factor for central cholinergic neurones is present in both normal and Alzheimer brain tissue.
    Atterwill CK; Bowen DM
    Acta Neuropathol; 1986; 69(3-4):341-2. PubMed ID: 3962611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease.
    Francis PT
    Neurodegeneration; 1996 Dec; 5(4):461-5. PubMed ID: 9117563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical basis of dementia in Parkinson's disease.
    Hornykiewicz O; Kish SJ
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):185-90. PubMed ID: 6143610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal changes in Alzheimer's disease and cholinergic hypothesis.
    Rossor MN
    Lancet; 1983 Aug; 2(8347):465. PubMed ID: 6135958
    [No Abstract]   [Full Text] [Related]  

  • 18. Does 5-hydroxytryptamine influence cholinergic mechanisms in the central nervous system?
    Pepeu G; Garau L; Mulas ML
    Adv Biochem Psychopharmacol; 1974; 10():247-52. PubMed ID: 4276955
    [No Abstract]   [Full Text] [Related]  

  • 19. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease.
    Bowen DM; Allen SJ; Benton JS; Goodhardt MJ; Haan EA; Palmer AM; Sims NR; Smith CC; Spillane JA; Esiri MM; Neary D; Snowdon JS; Wilcock GK; Davison AN
    J Neurochem; 1983 Jul; 41(1):266-72. PubMed ID: 6306169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease.
    Scott HL; Pow DV; Tannenberg AE; Dodd PR
    J Neurosci; 2002 Feb; 22(3):RC206. PubMed ID: 11826152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.